Bob Baloh, Novartis Head of Neuroscience at NIBR (via Cedars-Sinai)
Novartis taps Roche's neuro and rare disease research lead to run neuroscience research
Even after agreeing to sell off $20 billion in shares back to Roche in November, Novartis got a bit more from its crosstown rival …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
